Increased use of colonoscopy screening could explain decrease in colorectal cancer rates
Use of colonoscopy for colorectal cancer screening could explain a significant decrease in the cancer's incidence over the past decade, according to a new study from researchers at the Stanford University School of Medicine. Although colonoscopy is now the most common colorectal cancer screening method, there has been conflicting evidence as to its effectiveness compared with sigmoidoscopy, a method that examines only a portion of the colon.
The team scrutinized data collected from more than 2 million patients over the past 20 years, and found that a drop in colorectal cancer incidence correlated with Medicare's extension of colonoscopy coverage in 2001.
"Widespread colonoscopy screening may actually be having an impact in the risk of colon cancer at the level of the general population," said Uri Ladabaum, MD, MS, associate professor of gastroenterology and hepatology and senior investigator for the study. The results will be published online Oct. 23 in Gastroenterology.
Colorectal cancer is the second-leading cause of cancer-related deaths in the United States, according to the federal Centers for Disease Control and Prevention. The American Cancer Society and other groups recommend colorectal cancer screening for people at average risk beginning at age 50. Colonoscopies are recommended once every 10 years for average-risk adults, and more often in those found to have precancerous lesions known as polyps.
Several methods are currently available for the screening. Less-invasive methods, such as stool sample analysis, cause minimal discomfort but some patients consider them a hassle, and the tests need to be performed regularly to be effective. And although these methods occasionally detect precancerous polyps, their primary purpose is detecting early stage cancers.
Colonoscopy and sigmoidoscopy are endoscopic screening methods used both for early cancer detection and for precancerous polyp removal. Sigmoidoscopy only extends into the lower (or distal) part of the colorectum, while colonoscopy extends beyond the lower colorectum and into the upper (or proximal) colon. Although sigmoidoscopy has demonstrated clear benefits in preventing cancers in the lower colorectum, U.S. doctors have increasingly relied on colonoscopy and have made it the most common method of colon cancer screening.
"The faith for a long time has been that looking more deeply into the colon must be better because we're looking at more of the colon," said Ladabaum. Despite the presumed benefits of colonoscopy, the actual superiority of the procedure as compared with sigmoidoscopy has been the subject of conflicting studies.
With the hope of shedding some light on this murky issue, Ladabaum's team examined available data on the surgery rates for colorectal cancer, and interpreted these in light of the dramatic rise in the use of colonoscopy that began more than a decade ago. The researchers analyzed data from more than 2 million patients collected from the Nationwide Inpatient Sample, a large database that includes more than 1,000 hospitals. Ladabaum and colleagues looked for trends in colorectal cancer surgery, which reflect cancer incidence. They also specifically looked for differences in rates of cancer in the lower versus the upper colon, as colonoscopy is hoped to have a benefit in preventing cancers in both areas due to its extended reach.
The results of the study suggest that increased use of colonoscopy may explain the decrease in incidence of upper colon cancer—through the identification, and removal, of precancerous polyps—in the last decade. The overall rate for removing, or resecting, colorectal cancer dropped from 71.1 to 47.3 per 100,000 persons between 1993 and 2009. Resection rates for lower colorectal cancer decreased gradually (at a rate of about 1.2 percent per year) from 1993 to 1999, and then dropped more steeply (to a rate of 3.8 percent per year) from 1999 to 2009. In contrast, the resection rate for upper colon cancer remained steady until 2002, and then started dropping at a rate of 3.1 percent per year until 2009.
These results support the idea that the drop in the incidence of lower colorectal cancer might be associated with screening in general, since some patients were already undergoing stool tests and sigmoidoscopy in the early 1990s, whereas the reduction in upper colon cancer incidence might be specifically associated with colonoscopy, Ladabaum said.
Interestingly, the drop in upper colon cancer incidence was seen not only for people within the suggested screening ages, but also for those over age 75. Currently, there is no consensus on whether to screen people older than 75, Ladabaum said. While some of these older patients may opt to get colonoscopies, he said he thinks these results could mean that colonoscopy screening at an earlier age prevents colorectal cancer later in life.
The availability of a screening technique that effectively detects and removes precancerous lesions makes colorectal cancer a uniquely preventable cancer, he added. "We really do have an opportunity to find the pre-cancers, before there is even a cancer there," said Ladabaum.
Journal reference:
Gastroenterology
Provided by
Stanford University Medical Center
-
Too many americans skipping colon cancer screening
Mar 02, 2012 |
not rated yet |
0
-
The Medical Minute: Screening can prevent colorectal cancer
Mar 23, 2010 |
not rated yet |
0
-
Study confirms colonoscopy associated with reduced colorectal cancer incidence
Oct 02, 2008 |
not rated yet |
0
-
Study finds sigmoidoscopy reduces colorectal cancer rates
May 21, 2012 |
not rated yet |
0
-
African Americans less likely than whites to get colonoscopy despite family history of colon cancer
Mar 25, 2008 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
5 hours ago
-
If you became brain-dead, would you want them to pull the plug?
21 hours ago
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
-
Marie Curie's leukemia
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
ASCO: combo antibody therapy effective for melanoma
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer
16 hours ago |
not rated yet |
0
Risk factors ID'd for poor cutaneous cell CA outcomes
(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...
Cancer
17 hours ago |
not rated yet |
0
|
Physical & emotional impairments common, often untreated in people with cancer
A new review finds cancer survivors suffer a diverse and complex set of impairments, affecting virtually every organ system. Writing in CA: A Cancer Journal for Clinicians, Julie Silver, M.D., associate professor at Harvar ...
Cancer
21 hours ago |
not rated yet |
0
Calif. doc with 'cancer cure' gets 14 years prison (Update)
(AP)—A California doctor has been sentenced to 14 years in federal prison for bilking her patients out of more than $1 million by promising that an herbal supplement could cure late-stage cancer and other diseases.
Cancer
22 hours ago |
not rated yet |
0
New protein-targeting drug shows promise in early trial for patients with high-risk CLL
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
Cancer
May 17, 2013 |
not rated yet |
0
|
AIDS science at 30: 'Cure' now part of lexicon
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
Melon focus headband turns to Kickstarter for rollout plans
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
Temporal processing in the olfactory system
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
Now we know why old scizophrenia medicine works on antibiotics-resistant bacteria
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...
Individuals who drink heavily and smoke may show 'early aging' of the brain
Treatment for alcohol use disorders works best if the patient actively understands and incorporates the interventions provided in the clinic. Multiple factors can influence both the type and degree of neurocognitive abnormalities ...